Modelling Cost Effectiveness and Cost Utility of Sequential DMARD Therapy Including Leflunomide for Rheumatoid Arthritis in Germany: II. The Contribution of Leflunomide to Efficiency

Author： Schädlich Peter K.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.23, Iss.4, 2005-01, pp. : 395-420

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Modelling Cost Effectiveness and Cost Utility of Sequential DMARD Therapy Including Leflunomide in Rheumatoid Arthritis in Germany: I. Selected DMARDs and Patient-Related Costs

By Schädlich Peter K.  

PharmacoEconomics, Vol. 23, Iss. 4, 2005-01 ,pp. : 377-393

Adis International

Access to resources Recommend Favorite

Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis

By Alldred A.   Emery P.  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 1, 2001-01 ,pp. : 125-137

Informa Healthcare

Access to resources Recommend Favorite

Leflunomide in Combination Therapy for Rheumatoid Arthritis

By Savage Ruth L.  

Drug Safety, Vol. 33, Iss. 6, 2010-06 ,pp. : 523-526

Adis International

Access to resources Recommend Favorite

Leflunomide for the treatment of rheumatoid arthritis

By Miceli-Richard Corinne   Dougados Maxime  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 6, 2003-06 ,pp. : 987-997

Informa Healthcare

Access to resources Recommend Favorite

Adding leflunomide to DMARD sequence in Germany pays off

By  

Inpharma, Vol. 1, Iss. 1487, 2005-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite